VRAX קפיטליזציה חשבונאית Virax Biolabs

As an authoritative player in early virus detection, Virax Biolabs Group (VRAX) develops precise immune systems, generating revenue through the sale of diagnostic kits for influenza and hepatitis monitoring. This chart reflects current share prices fixed at 0.02. Meanwhile, the brand's production capacities are operating normally, undergoing technical modernization to launch updated test series.

Book value capitalization represents a daily revaluation of net assets, capturing the real value of equity under inflationary pressure. The current value of 0.02 for the firm's book capital reflects the financial stability of Virax Biolabs Group (VRAX), which is critical for scaling the diagnostic laboratory network and expanding test distribution into emerging markets.